Efavirenz

Efavirenz-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View Download All PDFs List View Archive

loading
Unitary pharmaceutical dosage form
Bristol-myers Squibb & Gilead Sciences, Llc
March 23, 2017 - N°20170079999

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir df are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir df (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Process for the preparation of efavirenz and devices suitable therefore
Max-planck-gesellschaft Zur FÖrderung Der Wissenschaften E.v.
March 02, 2017 - N°20170057937

The invention relates to a process for the preparation of efavirenz via an efficient transition metal catalyzed cyclization, to a device suitable to perform such process as well as to novel intermediates.
Process for the preparation of efavirenz using keton solvents
F.i.s. - Fabbrica Italiana Sintetici S.p.a.
January 12, 2017 - N°20170008861

An improved process for the preparation of efavirenz which avoids the distillations of the solvents is provided.
Efavirenz Patent Pack
Download + patent application PDFs
Efavirenz Patent Applications
Download + Efavirenz-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Efavirenz-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Increased dosage of efavirenz for the treatment of cancer
Alienor Farma
December 24, 2015 - N°20150366871

The invention is based on the finding that an increased daily dose of efavirenz should be used for the treatment of cancer compared to the daily dose used in the treatment of aids. The invention thus relates to the use of efavirenz for preparing a medicament intended for the treatment of cancer, wherein efavirenz is administered at a dose generating ...
Unitary pharmaceutical dosage form
Bristol-myers Squibb & Gilead Sciences, Llc
June 25, 2015 - N°20150174147

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir df are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir df (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Pharmaceutical compositions of anti-viral compounds and process for preparation thereof
Bristol-myers Squibb & Gilead Sciences, Llc
May 21, 2015 - N°20150141376

Pharmaceutical compositions of anti-viral compounds, process for preparation and method of using the same are provided. Particularly, the present invention relates to chemically stable pharmaceutical compositions of efavirenz, emtricitabine and tenofovir disoproxil fumarate with optionally one or more pharmaceutically acceptable excipients, process for preparation and method for the treatment or prevention of the symptoms or effects of an hiv infection ...
Efavirenz Patent Pack
Download + patent application PDFs
Efavirenz Patent Applications
Download + Efavirenz-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Efavirenz-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method and composition for pharmaceutical product
Gilead Sciences, Inc.
December 18, 2014 - N°20140370102

This invention is directed to a composition comprising dry granulated tenofovir df and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir df containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir df.
Combination therapy
Gilead Sciences, Inc.
December 11, 2014 - N°20140364389

The present invention relates to a combination therapy for treating an hiv infection or inhibiting integrase comprising (s)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“compound a”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-hiv agent. In some embodiments of the ...
Compositions of efavirenz
Gilead Sciences, Inc.
August 07, 2014 - N°20140220140

The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-e-polyethylene glycol-succinate (vit-e-peg-succinate), a polyoxyethylene sorbitan fatty acid ester, n-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl ...
Highly loaded amorphous efavirenz composition and process for preparing the same
Gilead Sciences, Inc.
May 29, 2014 - N°20140148449

A stable and high loading ternary solid dispersion composition comprising (a) about 50% wt. To about 90% wt. Of amorphous efavirenz; (b) about 10% wt. To about 50% wt. Of polyvinyl pyrrolidone (pvp), a first polymer; (c) about 1% wt. To about 30% wt. Of a water-soluble second polymer; and (d) optionally about 0. 1% wt. To about 50% wt. Of at least one pharmaceutically acceptable excipient. Also discloses ...
Method and composition for pharmaceutical product
Gilead Sciences, Inc.
February 06, 2014 - N°20140037732

This invention is directed to a composition comprising dry granulated tenofovir df and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir df containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir df.
Unitary pharmaceutical dosage form
Gilead Sciences, Inc.
February 06, 2014 - N°20140037724

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir df are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir df (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Efavirenz Patent Pack
Download + patent application PDFs
Efavirenz Patent Applications
Download + Efavirenz-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Efavirenz-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.